Sign in
Not yet recruitingEarly phase 1

Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia

Key facts

Who runs it
Chinese PLA General Hospital
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Early phase 1
People taking part
250 people, planned
Started
1 Jun 2026
Expected to end
31 Dec 2029
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • YHDF placebo
  • Bacteriophage Placebo
  • YHDF Drug
  • Bacteriophage
Record updated
29 May 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome
  • Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa
  • Aged 18 to 85 years old
  • Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy
  • Patients or their family members have fully read, understood and signed the informed consent form

Who cannot take part

  • Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases
  • Patients who have received mechanical ventilation for more than 60 days prior to enrollment
  • Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD)
  • Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula
  • Women who are pregnant or lactating
  • Patients with immunodeficiency
  • Patients with incomplete sampling or clinical data
  • Patients judged by the researchers as unsuitable for participation in this study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Pneumonia

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.

The 4 groups in the trial

  • YHDF Placebo + Bacteriophage Placebo GroupPlacebo, for comparison

    7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo

    Treatment: YHDF placebo and Bacteriophage Placebo

  • YHDF Placebo + Bacteriophage GroupExisting treatment, for comparison

    7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo

    Treatment: YHDF placebo and Bacteriophage

  • YHDF Drug + Bacteriophage Placebo GroupExisting treatment, for comparison

    7-14 days treatment with YHDF, 7-14 days treatment with phage placebo

    Treatment: Bacteriophage Placebo and YHDF Drug

  • YHDF Drug + Bacteriophage GroupExisting treatment, for comparison

    7-14 days treatment with YHDF, 7-14 days treatment with phage

    Treatment: YHDF Drug and Bacteriophage

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli
Criteria questions
Built from NCT07612605, who can take part
Record updated
29 May 2026